Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients

Articolo

Data di Pubblicazione:

2021

Citazione:

Fuso, P., Di Salvatore, M., Santonocito, C., Guarino, D., Autilio, C., Mule, A., Arciuolo, D., Rinninella, A., Mignone, F., Ramundo, M., Di Stefano, B., Orlandi, A., Capoluongo, E. D., Nicolotti, N., Franceschini, G., Sanchez, A. M., Tortora, G., Scambia, G., Barone, C., Cassano, A., Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients, <>, 2021; 11 (8): 1-17. [doi:10.3390/jpm11080816] [http://hdl.handle.net/10807/190389]

Abstract:

Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospec-tively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next‐Generation‐Sequencing (NGS) system. Results: Event‐free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let‐7a‐5p (EFS p = 0.006; OS p = 0.0001), mirR‐100‐5p (EFS s p = 0.01; OS p = 0.03), miR‐ 101‐3p (EFS p = 0.05; OS p = 0.01), and miR‐199a‐3p (EFS p = 0.02; OS p = 0.01) in post‐NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let‐7a‐5p was significantly associated with EFS (p = 0.009) and OS (p = 0.0008). Conclusion: Up‐regulation of the above miRNAs could represent biomarkers in breast cancer.

Tipologia CRIS:

Articolo in rivista, Nota a sentenza

Keywords:

Breast cancer treatment; Chemotherapy; Integrated ther-apies; MiRNAs; Next‐generation‐sequencing; Personalized medicine; Precision medicine; Subtypes breast cancer; Target therapy

Elenco autori: